Le Lézard
Classified in: Health

Successful USFDA inspection of Asymchem Tianjin 2 development and commercial manufacturing facility

TIANJIN, China, Sept. 12, 2018 /PRNewswire/ -- Asymchem, a leading custom manufacturer of intermediates and API's for the life sciences industry, today announced that its Tianjin 2 site, a multi-purpose development and commercial API manufacturing facility, successfully passed the U.S. Food and Drug Administration (USFDA) general GMP reinspection conducted between July 23-26, 2018 with no Form 483 issued.

Speaking to the success of yet another FDA inspection, Dr. Zhou Yan, VP Quality at Asymchem states, "Our teams invest in and conduct continuous improvements to ensure the highest level of compliance and inspection readiness across all Asymchem sites." Asymchem's previous USFDA inspection of the Tianjin 2 site in 2014, as well as the most recent Asymchem Dunhua 1 and Fuxin 1 facilities in March 2017 and March 2018 respectively, also resulted in no Form 483 observations.

Dr. Hao Hong, Chairman and CEO of Asymchem Group, remarked, "I am extremely proud of the result as the Asymchem team proves yet again our robust quality system together with unyielding management commitment meets the highest quality standards in the manufacture of GMP products."

To keep up with increasing demand, Asymchem is expanding the Tianjin 2 site to include peptide manufacturing capability as well as expanding low volume API manufacturing capacity. Both will be operational by late 2018.

About Asymchem
Asymchem is a full service CMC CDMO of API's for the global pharmaceutical industry, providing compliant and sustainable manufacturing solutions worldwide over the lifecycle of a drug. Capabilities include dedicated HPAPI, in-house enzyme evolution and fermentation for biotransformations, end-to-end continuous flow development and application, hydrogenation, cryogenic capabilities, dedicated carbapenem manufacture, and others. Founded in 1997, Asymchem employs 2800 personnel within China over 6 manufacturing sites. Asymchem has a successful history of USFDA, Australian TGA, Chinese cFDA and Korean MFDS inspections.


SOURCE Asymchem

These press releases may also interest you

16 nov 2018
Johnson Fistel, LLP announced that a class action has been commenced on behalf of purchasers of Trevena, Inc. common stock during the period between May 2, 2016 and October 9, 2018 (the "Class Period"). If you wish to serve as lead plaintiff, you...

16 nov 2018
LAKE ORION, Mich., Nov. 16, 2018 /PRNewswire-PRWeb/ -- Most of the time, vaginal discharge is perfectly normal and an essential function in the female reproductive system. However, changes in the color, smell, or consistency could be signs of an...

16 nov 2018
ROCHESTER, Mich., Nov. 16, 2018 /PRNewswire-PRWeb/ -- Women's Excellence in Rochester, Michigan, will now offer treatment options to patients suffering from chronic pelvic pain. In addition to oncology services, the new center will specialize in the...

16 nov 2018
As American Diabetes Month kicks off this November to raise awareness for the disease that impacts more than 30 million Americans, MobileHelp® Healthcare, a leader in personal and enterprise healthcare technology solutions, announced expanded...

16 nov 2018
PITTSBURGH, Nov. 16, 2018 /PRNewswire-PRWeb/ -- MedVet is pleased to announce its expansion into Pittsburgh, Pennsylvania with the addition of University Veterinary Specialists (UVS), now known as MedVet Pittsburgh. The City Vets and VetNow divisions...

16 nov 2018
PHOENIX, Nov. 16, 2018 /PRNewswire-PRWeb/ -- America's families are buckling under the financial burden of caring for their children and their aging parents at the same time. Most turn a blind eye to the Silver Tsunami desperately hoping it won't hit...

News published on 12 september 2018 at 19:39 and distributed by: